Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Finerenone plus ACEI/ARB in pediatric chronic kidney disease with proteinuria
2021-002071-19Phase 3Active
- Sponsor
- Bayer
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic kidney disease (CKD) comparing Finerenone plus ACEI/ARB with Placebo plus ACEI/ARB (2 arms). Primary endpoint: Mean reduction from baseline to Month 6 in Urinary Protein-to-Creatinine Ratio. Started Oct 2021; status: active.
02
Drugs
finerenone
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2021-002071-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002071-19.